NCT02590081

Brief Summary

This is a prospective, randomized, double-blind, parallel group trial to assess the efficacy and safety of intravenous dextrose 5% solution compare with normal saline (standard care) in wash back procedure during haemodialysis in patients with end stage renal failure (ESRF) with respect to systolic blood pressure control over 3 months period. The primary objective is to establish efficacy of 5% dextrose solution compared with normal saline (0.9% sodium chloride solution) with respect to systolic blood pressure control in subjects with end stage renal failure (ESRF) on regular hemodialysis. Secondary objectives include monitoring the change in body weight, thirst level and body fluid volume.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
434

participants targeted

Target at P75+ for phase_4

Geographic Reach
1 country

15 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

October 27, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 28, 2015

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2016

Completed
Last Updated

October 28, 2015

Status Verified

October 1, 2015

Enrollment Period

1 year

First QC Date

October 27, 2015

Last Update Submit

October 27, 2015

Conditions

Keywords

Normal salineDestrose 5%Blood pressureInterdialytic weight gainthirst levelEnd Stage Renal Failure

Outcome Measures

Primary Outcomes (1)

  • systolic blood pressure control

    post intervention systolic blood pressure reduction compared to baseline

    Time from week 0 until week 12

Secondary Outcomes (4)

  • Interdialytic weight gain

    Time from week 0 until week 12

  • thirst level

    Time from week 0 and week 12

  • intradialytic event

    Time from week 0 until week 12

  • adverse events

    Time from week 0 until week 12

Study Arms (2)

Normal saline

ACTIVE COMPARATOR

Normal saline will be used for wash back procedure at the end of hemodiaysis.

Drug: normal saline

dextrose 5%

EXPERIMENTAL

Dextrose 5% will be used for wash back procedure at the end of hemodiaysis.

Drug: Dextrose 5%

Interventions

dextrose 5%
Normal saline

Eligibility Criteria

Age18 Years - 74 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ambulatory, clinically stable maintenance HD patients on a thrice weekly HD regime.
  • Have regular hemodialysisforat least 6 months or more.
  • Willing and able to provide written, signed informed consent after the nature of the study has been explained.
  • Willing and able to comply with all study procedures.
  • Age ≥18 years; Age \< 75 years old

You may not qualify if:

  • Diabetes mellitus, Malignancy, Pregnancy
  • Inability or unwillingness to provide written consent.
  • Inability or unwillingness to comply with the requirements of the protocol as determined by the investigator.
  • Simultaneous participation in another clinical study except observational trials
  • Any psychological condition which could interfere with the patient's ability to comply with the study protocol
  • Inability to perform a blood pressure measurement on the upper limb
  • Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period.
  • Life expectancy \< 6 months
  • Recent acute myocardial infarction, congestive cardiac failure, stroke, angina or ICU admission within last 6 months,
  • Planned to migrate/move out of the city
  • Alcohol abuse/ drug abuse within last 6 months
  • Missed \> 2 hemodialysis sessions over 1 month
  • Requiring non- cuff catheter for hemodialysis
  • Admitted for major infection within the last one month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Hospital Sultanah Bahiyah, Alor Setar

Alor Star, Kedah, 05460, Malaysia

Location

UKM Medical Centre

Cheras, Kuala Lumpur, 56000, Malaysia

Location

Hospital Kuala Lumpur

Kuala Lumpur, Kuala Lumpur, 50586, Malaysia

Location

UM Medical Centre

Kuala Lumpur, Kuala Lumpur, 59100, Malaysia

Location

Hospital Tuanku Jaafar

Seremban, Negeri Sembilan, 70300, Malaysia

Location

Hospital Tengku Ampuan Afzan

Kuantan, Pahang, 25100, Malaysia

Location

Hospital Balik Pulau

Balik Pulau, Pulau Pinang, 11000, Malaysia

Location

Hospital Bukit Mertajam

Bukit Mertajam, Pulau Pinang, 14000, Malaysia

Location

Penang Hospital

George Town, Pulau Pinang, 10990, Malaysia

Location

Hospital Kepala Batas

Kepala Batas, Pulau Pinang, 13200, Malaysia

Location

Seberang Jaya Hospital

Seberang Jaya, Pulau Pinang, 13700, Malaysia

Location

Hospital Sungai Bakap

Sungai Bakap, Pulau Pinang, 14200, Malaysia

Location

Miri Hospital

Miri, Sarawak, 98000, Malaysia

Location

Selayang Hospital

Selayang Baru Utara, Selangor, 68100, Malaysia

Location

Hospital Serdang

Serdang, Selangor, 43400, Malaysia

Location

Related Publications (2)

  • Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol. 2011;34(4):381-90. doi: 10.1159/000331067. Epub 2011 Sep 2.

    PMID: 21893975BACKGROUND
  • Brennan JM, Ronan A, Goonewardena S, Blair JE, Hammes M, Shah D, Vasaiwala S, Kirkpatrick JN, Spencer KT. Handcarried ultrasound measurement of the inferior vena cava for assessment of intravascular volume status in the outpatient hemodialysis clinic. Clin J Am Soc Nephrol. 2006 Jul;1(4):749-53. doi: 10.2215/CJN.00310106. Epub 2006 May 24.

    PMID: 17699282BACKGROUND

MeSH Terms

Conditions

Kidney Failure, ChronicRenal Insufficiency, Chronic

Interventions

Saline Solution

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Loke Meng Ong, FRCP

    Penang Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Loke Meng Ong, FRCP

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

October 27, 2015

First Posted

October 28, 2015

Study Start

October 1, 2015

Primary Completion

October 1, 2016

Last Updated

October 28, 2015

Record last verified: 2015-10

Locations